Professor of Neurology and Neurogenetics, University of Bergen
Clinical neurologist whose research looks at the role of mitochondrial dysfunction in Parkinson's disease. He led the NADPARK and NOPARK trials of nicotinamide riboside in Parkinson's and directs the K.G. Jebsen Center for Translational Research in Parkinson's Disease at the University of Bergen. His group has worked with Niagen Bioscience's external research program since 2018.
WHAT TO WATCHFurther NOPARK analyses on whether some patient subgroups responded differently to nicotinamide riboside.
In a year-long study of 410 people with early Parkinson’s, the supplement nicotinamide riboside (NR) raised a molecule cells use for energy, but did not slow the disease. Symptoms got slightly worse than on a dummy pill.
Charalampos Tzoulis7 sources · 5 min